Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: INTERFERON-BETA - THERAPEUTIC USE , . Treffer: 12
2016
Sormani, MP; Gasperini, C; Romeo, M; Rio, J; Calabrese, M; Cocco, E; Enzinger, C; Fazekas, F; Filippi, M; Gallo, A; Kappos, L; Marrosu, MG; Martinelli, V; Prosperini, L; Rocca, MA; Rovira, A; Sprenger, T; Stromillo, ML; Tedeschi, G; Tintorè, M; Tortorella, C; Trojano, M; Montalban, X; Pozzilli, C; Comi, G; De Stefano, N; MAGNIMS study group
Assessing response to interferon-β in a multicenter dataset of patients with MS.
Neurology. 2016; 87(2):134-140
Doi: 10.1212/WNL.0000000000002830
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2014
Hegen, H; Millonig, A; Bertolotto, A; Comabella, M; Giovanonni, G; Guger, M; Hoelzl, M; Khalil, M; Killestein, J; Lindberg, R; Malucchi, S; Mehling, M; Montalban, X; Polman, CH; Rudzki, D; Schautzer, F; Sellebjerg, F; Sørensen, PS; Deisenhammer, F
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Mult Scler. 2014; 20(5):577-587
Doi: 10.1177/1352458513503597
Web of Science
PubMed
FullText
FullText_MUG
Paulson, KG; Tegeder, A; Willmes, C; Iyer, JG; Afanasiev, OK; Schrama, D; Koba, S; Thibodeau, R; Nagase, K; Simonson, WT; Seo, A; Koelle, DM; Madeleine, M; Bhatia, S; Nakajima, H; Sano, S; Hardwick, JS; Disis, ML; Cleary, MA; Becker, JC; Nghiem, P
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.
Cancer Immunol Res. 2014; 2(11):1071-1079
Doi: 10.1158/2326-6066.CIR-14-0005
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2010
Radue, EW; Stuart, WH; Calabresi, PA; Confavreux, C; Galetta, SL; Rudick, RA; Lublin, FD; Weinstock-Guttman, B; Wynn, DR; Fisher, E; Papadopoulou, A; Lynn, F; Panzara, MA; Sandrock, AW; SENTINEL Investigators
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
J Neurol Sci. 2010; 292(1-2):28-35
Doi: 10.1016/j.jns.2010.02.012
Web of Science
PubMed
FullText
FullText_MUG
van den Elskamp, IJ; Boden, B; Dattola, V; Knol, DL; Filippi, M; Kappos, L; Fazekas, F; Wagner, K; Pohl, C; Sandbrink, R; Polman, CH; Uitdehaag, BMJ; Barkhof, F
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
Neuroradiology. 2010; 52(10):875-881
Doi: 10.1007/s00234-009-0645-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2006
Lutterotti, A; Kuenz, B; Gredler, V; Khalil, M; Ehling, R; Gneiss, C; Egg, R; Deisenhammer, F; Berger, T; Reindl, M
Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
J Neuroimmunol. 2006; 181(1-2):145-149
Doi: 10.1016/j.jneuroim.2006.09.002
Web of Science
PubMed
FullText
FullText_MUG
Maier, K; Kuhnert, AV; Taheri, N; Sättler, MB; Storch, MK; Williams, SK; Bähr, M; Diem, R
Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.
Am J Pathol. 2006; 169(4):1353-1364
Doi: 10.2353/ajpath.2006.060159
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2005
Neuhaus, O; Stüve, O; Archelos, JJ; Hartung, HP
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
J NEUROL SCI 2005 233: 173-177.
Doi: 10.1016/j.jns.2005.03.030
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2004
Rieckmann, P; Toyka, KV; Bassetti, C; Beer, K; Beer, S; Buettner, U; Chofflon, M; Götschi-Fuchs, M; Hess, K; Kappos, L; Kesselring, J; Goebels, N; Ludin, HP; Mattle, H; Schluep, M; Vaney, C; Baumhackl, U; Berger, T; Deisenhammer, F; Fazekas, F; Freimüller, M; Kollegger, H; Kristoferitsch, W; Lassmann, H; Markut, H; Strasser-Fuchs, S; Vass, K; Altenkirch, H; Bamborschke, S; Baum, K; Benecke, R; Brück, W; Dommasch, D; Elias, WG; Gass, A; Gehlen, W; Haas, J; Haferkamp, G; Hanefeld, F; Hartung, HP; Heesen, C; Heidenreich, F; Heitmann, R; Hemmer, B; Hense, T; Hohlfeld, R; Janzen, RW; Japp, G; Jung, S; Jügelt, E; Koehler, J; Kölmel, W; König, N; Lowitzsch, K; Manegold, U; Melms, A; Mertin, J; Oschmann, P; Petereit, HF; Pette, M; Pöhlau, D; Pohl, D; Poser, S; Sailer, M; Schmidt, S; Schock, G; Schulz, M; Schwarz, S; Seidel, D; Sommer, N; Stangel, M; Stark, E; Steinbrecher, A; Tumani, H; Voltz, R; Weber, F; Weinrich, W; Weissert, R; Wiendl, H; Wiethölter, H; Wildemann, U; Zettl, UK; Zipp, F; Zschenderlein, R; Izquierdo, G; Kirjazovas, A; Packauskas, L; Miller, D; Koncan Vracko, B; Millers, A; Orologas, A; Panellus, M; Sindic, CJ; Bratic, M; Svraka, A; Vella, NR; Stelmasiak, Z; Selmaj, K; Bartosik-Psujik, H; Mitosek-Szewczyk, K; Belniak, E; Mochecka, A; Bayas, A; Chan, A; Flachenecker, P; Gold, R; Kallmann, B; Leussink, V; Mäurer, M; Ruprecht, K; Stoll, G; Weilbach, FX; Multiple Sclerosis Therapy Consensus Group
Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
J Neurol. 2004; 251(11):1329-1339
Doi: 10.1007/s00415-004-0537-6
Web of Science
PubMed
FullText
FullText_MUG
Thompson, A; Sorensen, PS; Montalban, X; Cook, S; Goodkin D, Filippi M, Kappos L, Cohen J, Ebers G, Cutter G, Fazekas F, Barkhof F, Miller A, Brooks BR, Noseworthy J, Lucchinetti C, Weinshenker B
Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis - Question and answer session.
MULT SCLER. 2004; 10 Suppl 1(1): S62; discussion 62-S62; discussion 64.
Doi: 10.1191/1352458504ms1033oa
Web of Science
PubMed
FullText
FullText_MUG
2003
Barkhof, F; Rocca, M; Francis, G; Van Waesberghe, JH; Uitdehaag, BM; Hommes, OR; Hartung, HP; Durelli, L; Edan, G; Fernández, O; Seeldrayers, P; Sørensen, P; Margrie, S; Rovaris, M; Comi, G; Filippi, M; Early Treatment of Multiple Sclerosis Study Group
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Ann Neurol. 2003; 53(6):718-724
Doi: 10.1002/ana.10551
Web of Science
PubMed
FullText
FullText_MUG
2000
Hartung, HP
NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence.
Lancet. 2000; 356(9235):1114-1114
Doi: 10.1016/S0140-6736(05)74558-X
Web of Science
PubMed
FullText
FullText_MUG